Poietis’ Post

Innovative! Let's make it happen because Type II Diabetes is a huge cost burden to the global economy despite it being a reversible disease. Insulin Resistance Syndrome, and it's consequences, is possibly THE biggest killer of human beings, right Tony Bartlett ? I tried to Educate UK Physicians when discussing and laughing "Avandia" (Rosiglitazone) in the UK, but they weren't quite ready for the truth, and we're entrenched in prescribing sulphasalazine, which forces the Pancreas to work much harder, thereby destroying the Islets of Langerhans, and stopping natural process of Insulin production in the human body. This was was very frustrating even in 2001, especially as we has NHS Pharmaceutical Advisors and N.I.C.E (National Institute for Climical Excellence) trying to stop Rosiglitazone from being prescribed as it was more expensive than the cheap "crap" that didn't work! Hey ho, that's the NHS National Institute for Curbing Expenditure for you !? Since the 1990's N.I.C.E have banned or restricted many groundbreaking medicines being available on NHS prescription, leading to a bigger financial burden on the NHS, human suffering and patients early death! Such is the ignorance. Quite ironic really don't you think?

Join this webinar to learn how a Single Entry Point can help industry, SMEs and startups access the comprehensive services in #nanopharmaceutical innovation offered by the PHOENIX-OITB partners. Register now! #pharma #CMC #GMP #manufacturing #webinar

RESISTANCE IS NOT AN OPTION

🔬 Pushing Scientific Frontiers! 🔬 The AC is proud to share the story of its first “spin out” company, Intrepid Labs. Intrepid is reshaping the landscape of drug delivery by leveraging the power of self-driving labs to rapidly optimize drug formulations. This collaborative effort between Intrepid and the AC underscores the pivotal role of partnerships between academia and industry in driving scientific progress. Congratulations to Alán Aspuru-Guzik, Dr. Christine Allen, Pauric Bannigan and Riley Hickman for all their success. Intrepid that embodies the spirit of scientific inquiry and collaborative problem-solving. With partners like Intrepid, the AC is forging new paths towards transformative breakthroughs in materials discovery. Read the full article here: https://lnkd.in/g_JadE8S #ScientificInnovation #DrugDiscovery #Biotechnology #ResearchCollaboration #AcceleratedMedicine #AIForHealthcare  

𝐒𝐜𝐢𝐞𝐧𝐭𝐢𝐟𝐢𝐜 𝐞𝐯𝐞𝐧𝐭: "𝐁𝐀𝐂𝐊 𝐓𝐎 𝐁𝐀𝐒𝐈𝐂: 𝐀𝐏𝐓𝐓 𝐈𝐍𝐃𝐈𝐂𝐀𝐓𝐈𝐎𝐍𝐒, 𝐋𝐈𝐌𝐈𝐓𝐀𝐓𝐈𝐎𝐍𝐒, 𝐏𝐑𝐄𝐀𝐍𝐀𝐋𝐘𝐓𝐈𝐂 𝐏𝐈𝐓𝐅𝐀𝐋𝐋𝐒 𝐀𝐍𝐃 𝐌𝐈𝐗𝐈𝐍𝐆 𝐒𝐓𝐔𝐃𝐘 𝐄𝐒𝐒𝐄𝐍𝐓𝐈𝐀𝐋𝐒” Proud to be one of the leaders in coagulation testing, Stago, a partner of Medigroup Vietnam, will organize a virtual webinar to deliver scientific information regarding aPTT, one of the essential basic coagulation assays. The objective focuses on aPTT’s principle, indications, interpretation, pitfalls and laboratory approach on how to address challenges to ensure comprehensive and nuanced assessment of a patient’s coagulation profile. ⏰ 𝗘𝘃𝗲𝗻𝘁 𝗱𝗮𝘁𝗲: Tuesday, 18/06/2024, 20:00-21:00 ➡️ 𝗙𝗼𝗿 𝗼𝗻𝗹𝗶𝗻𝗲 𝗿𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/dW7KuWf #Webinar #MediGroup #Stago #aPTT #Coagulation

🌟 Advancing Cellular Research with SPAchip Technology 🌟 A key advantage of our CytoCHECK SPAchip® technology is its lack of cytotoxicity, which allows long-term analysis. Through this breakthrough feature, researchers can conduct extended studies without compromising cell viability, leading to deeper insights and more reliable data over time. 🔬 Key Benefits: - Non-Cytotoxic: Ensures the health and viability of cells during prolonged studies. - Long-Term Analysis: Facilitates extended observation and data collection. - Versatile Applications: Suitable for a variety of research fields requiring continuous cell monitoring. 📊 In the attached picture, you can see how SPAchip® technology compares favorably with other staining methods, highlighting its effectiveness and compatibility with long-term cellular analysis. Join us in revolutionizing cellular research by leveraging the powerful capabilities of SPAchip® technology! #CellularResearch #SPAchip #Innovation #Biotech #LongTermAnalysis #NonCytotoxic #ScientificBreakthrough

Showcasing how data is playing an unprecedented role in driving advancements in drug research and development (R&D). With the evolution of data standards and enhanced data fidelity, we are now able to obtain profound insights from datasets. In silico and translational science solutions are instrumental in the transformation of raw data into actionable information and ultimately into valuable knowledge that fuels innovation in the pharmaceutical industry.

What a way to start the day! Speaking in a webinar with my colleagues on our In silico and translational science solutions. #webinar #instem #insilico #translationalresearch

💡At NBIC, our aim is to connect scientists specialising in biofilms across the UK, and to provide a mechanism for industrial partners to explore their unmet needs with NBIC partners. ⭐ NBIC industry membership provides industry with an additional layer of support from NBIC experts and exclusive access to a range of specialised services, providing members with the tools to facilitate the exchange of challenges, solutions, and ideas in the biofilm sector. Benefits include: 🤝 Curated searches and partnering set up by our specialist Innovation Team 📝 Participation in translational project applications 🌱 Bespoke funding insights based on company sectors 🎓 Access to NBIC PhD programmes via Collaborative Training Partnerships 📬 Membership newsletter 📈 Access to NBIC funded reports at a reduced rate 👥 NBIC Members Day – an annual, themed applied meeting 👩💻 Concessionary access to NBIC meetings, webinars and training 🔬Access to specialist information on university capabilities and facilities. Find out more ➡️ https://lnkd.in/ehS9rTTf #biofilm #biofilms #membership #industry #innovation #research

Capsida’s Chakameh Azimpour, Ph.D will be presenting a poster at the 2024 PDA Advanced Therapy Medicinal Products Conference:   📅 Date: 24-25 June 2024 📍 Location: Amsterdam, The Netherlands   The poster, entitled "Development of a dual reporter cargo and systemic incorporation of a highly flexible, benchtop automation system to facilitate rAVV9 based novel capsid development and characterization," showcases innovative research that highlights the breadth of Capsida’s analytical development expertise in characterizing novel engineered capsids.   This work is a collaborative effort by a talented team of Capsida researchers: Paul Denis, Kevin Chu, Jesse Granados, Regan Sobaje, Claire S., Leandro Fernandez, Tiffany Morrison, Lysa-Anne Volpe, Chakameh Azimpour, Ph.D.   Well done to the whole team!   #AdvancedTherapies #PDAConference #CapsidDevelopment #BiotechInnovation #ScientificResearch #AutomationInScience #GeneTherapy #ATMP #AdvancedTherapyMedicinalProduct